Overview Dividends

(COO) The Cooper Companies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2166485019

Contact Lenses, Fertility Devices, Intrauterine Devices, Surgical Instruments

Health Care Supplies
Market Cap in USD: 16,451m

IPO / Inception: 1983-12-30
Return 12m vs S&P 500: -23.2%

EPS (Earnings per Share)

EPS CAGR: -24.14%
EPS Trend: -81.3%

Last SUE: 1.63
Qual. Beats: 3

Revenue

Rev. CAGR: 8.40%
Rev. Trend: 97.3%

Last SUE: 0.30
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	27.7%
Value at Risk 5%th	40.8%
Relative Tail Risk	-10.39%

Reward TTM
Sharpe Ratio	-0.25
Alpha	-25.37
CAGR/Max DD	0.00

Character TTM
Hurst Exponent	0.365
Beta	0.790
Beta Downside	0.660

Drawdowns 3y
Max DD	42.17%
Mean DD	14.83%
Median DD	10.79%

Description: COO The Cooper Companies October 30, 2025

The Cooper Companies (NASDAQ:COO) operates through two distinct businesses: CooperVision, which designs and sells a broad portfolio of contact lenses-including toric, multifocal, and spherical lenses-to address astigmatism, presbyopia, myopia, and other refractive errors across the Americas, Europe, the Middle East, Africa, and Asia-Pacific; and CooperSurgical, which focuses on family- and women-health products such as fertility consumables, intra-uterine contraceptive devices, cryostorage services, and genomic testing, sold to healthcare professionals and institutions worldwide.

In fiscal 2023, CooperVision generated roughly $3.0 billion in revenue, driven by a 12% year-over-year increase in myopia-control lens sales-a segment benefiting from rising myopia prevalence among children and young adults. CooperSurgical contributed about $1.2 billion, with fertility-related services growing at a compound annual growth rate (CAGR) of 9% since 2020, reflecting global demand for assisted-reproductive technologies and expanding cord-blood banking. Both segments are sensitive to macro-economic factors such as discretionary consumer spending, insurance reimbursement policies, and demographic trends (e.g., aging populations increasing demand for presbyopic lenses).

For a deeper quantitative assessment of COO’s valuation dynamics, you may find the ValueRay platform’s analyst tools useful for exploring forward-looking cash-flow models and peer-group benchmarks.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (374.9m TTM) > 0 and > 6% of Revenue (6% = 245.6m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA 1.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 24.28% (prev 23.84%; Δ 0.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 796.1m > Net Income 374.9m (YES >=105%, WARN >=100%)

Net Debt (2.67b) to EBITDA (1.02b) ratio: 2.62 <= 3.0 (WARN <= 3.5)

Current Ratio 1.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (198.1m) change vs 12m ago -1.49% (target <= -2.0% for YES)

Gross Margin 64.32% (prev 66.64%; Δ -2.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 33.12% (prev 31.63%; Δ 1.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.89 (EBITDA TTM 1.02b / Interest Expense TTM 109.1m) >= 6 (WARN >= 3)

Altman Z'' 4.72

(A) 0.08 = (Total Current Assets 2.11b - Total Current Liabilities 1.11b) / Total Assets 12.39b

(B) 0.62 = Retained Earnings (Balance) 7.64b / Total Assets 12.39b

(D) 1.75 = Book Value of Equity 7.26b / Total Liabilities 4.16b

Total Rating: 4.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 55.39

1. Piotroski 6.0pt

2. FCF Yield 2.27%

3. FCF Margin 10.60%

4. Debt/Equity 0.34

5. Debt/Ebitda 2.62

6. ROIC - WACC (= -3.41)%

7. RoE 4.54%

8. Rev. Trend 97.26%

9. EPS Trend -81.35%

What is the price of COO shares?

As of December 27, 2025, the stock is trading at USD 82.62 with a total of 1,237,189 shares traded.
Over the past week, the price has changed by -0.16%, over one month by +6.00%, over three months by +22.31% and over the past year by -10.79%.

Is COO a buy, sell or hold?

The Cooper Companies has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy COO.

Strong Buy: 9
Buy: 2
Hold: 8
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the COO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	90.5	9.5%
Analysts Target Price	90.5	9.5%
ValueRay Target Price	88.8	7.5%

COO Fundamental Data Overview December 23, 2025

Market Cap USD = 16.45b (16.45b USD * 1.0 USD.USD)
P/E Trailing = 44.2513
P/E Forward = 18.3824
P/S = 4.02
P/B = 1.9684
P/EG = 2.1583
Beta = 1.049
Revenue TTM = 4.09b USD
EBIT TTM = 642.1m USD
EBITDA TTM = 1.02b USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 85.6m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.67b USD (from netDebt column, last quarter)
Enterprise Value = 19.12b USD (16.45b + Debt 2.78b - CCE 110.6m)
Interest Coverage Ratio = 5.89 (Ebit TTM 642.1m / Interest Expense TTM 109.1m)
FCF Yield = 2.27% (FCF TTM 433.7m / Enterprise Value 19.12b)
FCF Margin = 10.60% (FCF TTM 433.7m / Revenue TTM 4.09b)
Net Margin = 9.16% (Net Income TTM 374.9m / Revenue TTM 4.09b)
Gross Margin = 64.32% ((Revenue TTM 4.09b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 56.42% (prev 65.26%)
Tobins Q-Ratio = 1.54 (Enterprise Value 19.12b / Total Assets 12.39b)
Interest Expense / Debt = 0.88% (Interest Expense 24.4m / Debt 2.78b)
Taxrate = 27.57% (32.2m / 116.8m)
NOPAT = 465.1m (EBIT 642.1m * (1 - 27.57%))
Current Ratio = 1.89 (Total Current Assets 2.11b / Total Current Liabilities 1.11b)
Debt / Equity = 0.34 (Debt 2.78b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 2.62 (Net Debt 2.67b / EBITDA 1.02b)
Debt / FCF = 6.16 (Net Debt 2.67b / FCF TTM 433.7m)
Total Stockholder Equity = 8.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.02% (Net Income 374.9m / Total Assets 12.39b)
RoE = 4.54% (Net Income TTM 374.9m / Total Stockholder Equity 8.25b)
RoCE = 6.00% (EBIT 642.1m / Capital Employed (Equity 8.25b + L.T.Debt 2.46b))
RoIC = 4.32% (NOPAT 465.1m / Invested Capital 10.78b)
WACC = 7.73% (E(16.45b)/V(19.24b) * Re(8.93%) + D(2.78b)/V(19.24b) * Rd(0.88%) * (1-Tc(0.28)))
Discount Rate = 8.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF Debug] Terminal Value 72.35% ; FCFE base≈375.5m ; Y1≈321.3m ; Y5≈249.6m
Fair Price DCF = 19.93 (DCF Value 3.91b / Shares Outstanding 196.0m; 5y FCF grow -17.55% → 3.0% )
EPS Correlation: -81.35 | EPS CAGR: -24.14% | SUE: 1.63 | # QB: 3
Revenue Correlation: 97.26 | Revenue CAGR: 8.40% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-01-31): EPS=1.03 | Chg30d=+0.023 | Revisions Net=+7 | Analysts=16
EPS current Year (2026-10-31): EPS=4.51 | Chg30d=+0.109 | Revisions Net=+14 | Growth EPS=+9.4% | Growth Revenue=+5.5%
EPS next Year (2027-10-31): EPS=4.94 | Chg30d=+0.132 | Revisions Net=+12 | Growth EPS=+9.7% | Growth Revenue=+5.4%

Additional Sources for COO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle